Last updated: 20 October 2022 at 6:12am EST

Jeffrey Miner Net Worth



Jeffrey Miner biography

Dr. Jeffrey Miner serves as Chief Scientific Officer of the Company. He currently serves as co-founder and Chief Scientific Officer for Viscient, a position he has held since 2017. Prior to co-founding Viscient, Dr. Miner was Executive Director of Biology at AstraZeneca from 2013 to 2017, and Senior Director of Ardea Biosciences, a member of the AstraZeneca group, from 2008 to 2013. From 1993 to 2007, he held positions of increasing responsibility, including Head of Molecular and Cellular Biology, at Ligand Pharmaceuticals. Dr. Miner is currently a Faculty Advisor and Molecular Biology Institute Associate at San Diego State University and is a Board Member of the Scientific Advisory Board for ARTA Bioscience. Jeff completed a post-doctoral fellowship at the University of California San Francisco in 1993 on glucocorticoid receptor gene regulation in Keith Yamamoto's laboratory. He received his Ph.D. in Microbiology in 1989 from Oregon State University conducting graduate research in Virology in Dennis Hruby's laboratory and he received his B.S. degree in Biology from The College of Idaho in 1984. Mr. Miner has drug discovery experience in the Inflammation, Oncology, Endocrine, Hepatology and Cardiovascular therapeutic areas and his work has led to, or enhanced, the development of multiple marketed medicines. His target areas of expertise include Nuclear Receptors, Kinases and Transporters. He has published over 70 peer reviewed articles and book chapters and is an inventor on multiple patents.



What's Jeffrey Miner's mailing address?

Jeffrey's mailing address filed with the SEC is 11555 SORRENTO VALLEY ROAD, SUITE 100, , SAN DIEGO, CA, 92121.

Insiders trading at Organovo Inc

Over the last 13 years, insiders at Organovo Inc have traded over $8,085,375 worth of Organovo Inc stock and bought 386,250 units worth $661,443 . The most active insiders traders include Mark Kessel, Keith Murphy, and Adam K Stern. On average, Organovo Inc executives and independent directors trade stock every 112 days with the average trade being worth of $29,354. The most recent stock trade was executed by David Gobel on 15 November 2023, trading 19,607 units of ONVO stock currently worth $31,763.



What does Organovo Inc do?

organovo (nyse mkt: onvo) designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. the company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. these 3d human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. in addition to numerous scientific publications, their technology has been featured in the wall street journal, time magazine, the economist, and other outlets. organovo is changing the shape of medical research and practice.



Organovo Inc executives and stock owners

Organovo Inc executives and other stock owners filed with the SEC include: